Wolf-Georg Forssmann

This inventor holds 39 USPTO granted patents and 13 published patent applications, plus 6 CIPO patents and 15 EPO patents, primarily in Peptide Therapeutics. Top assignees: Pharis Biotec Gmbh, Haemopep Pharma Gmbh, Ipf Pharmaceuticals Gmbh. Active years: 1988-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wolf-Georg Forssmann. Retrieved from https://idiyas.com/inventor/wolf-georg-forssmann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 39 (Patent Applications = 13)

% Patents Active = 79.5

CIPO Patents = 6 (Patent Applications = 6)

EPO Patents = 15 (Patent Applications = 21)

Average Co-Inventor Count = 3.0

ph-index = 9

Forward Citations = 248(Granted Patents)

Location History:

Heidelberg DE (1995)
Heidelberg, DE (1988 - 1997)
Wies-Wambach, DE (2012)
Wles-Wambach, DE (2015)
Hannover, DE (1996 - 2019)
Hanover, DE (1998 - 2021)

Company Filing History:

Ipf Pharmaceuticals Gmbh

patents

4. 2 out of 2

Cardiopep Pharma Gmbh

Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft M.b.h.

Pharma Bissendorf Peptide Gmbh

Boehringer Mannheim Gmbh

patents

12. 1 out of 1

Kabigen Ab and Skandigen Ab

patent

13. 1 out of 1

Neopep Pharma Gmbh. & Co.

patent

14. 1 out of 1

Organon-Medizinisch-Molekularbiologische Forschungsgellschaft M.b.h

patent

15. 1 out of 1

Prof. Dr. Wolf-Georg Forssmann

patent

16. 1 out of 1

Relaxera Pharma Gmbh & Co. Kg I.g.

patent

17. 1 out of 1

Viro Pharmaceuticals Gmbh & Co. Kg

patent

18. 6 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 1988-2021

Loading Chart...

Areas of Expertise:

Polypeptides

Natriuretic Peptide

CXCR4 Antagonists

Phosphodiesterase Inhibitors

Peptide Hormones

Antibiotic Peptides

Gene Transfer Enhancer

Serine Proteinase Inhibitors

Cardiodilatin

Thrombocytopenia

Viral Infection Peptides

Bifidogenic Peptides

39 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11124540 - Polypeptides for the treatment of diseases (2021-09-21),

2. 10294272 - Peptides with antagonistic activities against natural CXCR4 (2019-05-21),

3. 10125169 - Protransduzin B, a gene transfer enhancer (2018-11-13),

4. 9434780 - Process for preparing human relaxin-2 (2016-09-06),

5. 9358271 - Use of natriuretic peptide for treating heart failure (2016-06-07),

6. 9045563 - CXC chemokine receptor 4 (CXCR4) antagonistic polypeptide (2015-06-02),

7. 9023794 - Use of natriuretic peptide for treating heart failure (2015-05-05),

8. 8791124 - Use of phosphordiesterase inhibitors in the treatment of prostatic diseases (2014-07-29),

9. 8710006 - Use of natriuretic peptide for treating heart failure (2014-04-29),

10. 8299031 - Human semen enhancer of viral infection peptides (SEVI) and their use (2012-10-30),

11. 8293711 - Use of natriuretic peptides for treating angioedema syndromes (2012-10-23),

12. 8106061 - Use of phosphodiesterase inhibitors in the treatment of prostatic diseases (2012-01-31),

13. 7741287 - Peptides for the treatment of herpes virus infections (2010-06-22),

14. 7732406 - Use of natriuretic peptide for treating heart failure (2010-06-08),

15. 7232796 - Medicament containing a tissue inhibitor of metalloproteinases-2 (TIMP-2) as an osteoanabolically active substance (2007-06-19),

Title: The Innovative Contributions of Wolf-Georg Forssmann

Introduction

Wolf-Georg Forssmann is a prominent inventor based in Hannover, Germany, recognized for his significant contributions to the field of biomedicine. With an impressive portfolio of 39 patents, Forssmann has made groundbreaking advancements in the treatment of diseases through innovative peptide technologies.

Latest Patents

Among his latest patents, Forssmann has developed novel polypeptides designed for therapeutic applications. One notable invention is a polypeptide characterized by the general amino acid sequence ZIXRWXXKXPXXSZ. This polypeptide features specific modifications at both the N-terminal and C-terminal amino acids that enhance its therapeutic potential. Another critical patent focuses on peptides that exhibit antagonistic activities against the natural CXCR4 receptor, demonstrating effectiveness in blocking HIV-1 NL4-3 infection, with an impressive IC value of less than 50 µM.

Career Highlights

Throughout his career, Forssmann has been affiliated with various organizations, including Pharis Biotec GmbH, where he has contributed to pioneering research and development efforts in biomedical innovation. His expertise in peptide synthesis and application has been fundamental in advancing methodologies used in disease treatment and prevention.

Collaborations

Forssmann has collaborated with notable colleagues in the scientific community, including Ludger Ständker and Markus Meyer. These partnerships have fostered the exchange of ideas and expertise, enhancing the research capabilities within the field and leading to the successful development of innovative therapies.

Conclusion

In conclusion, Wolf-Georg Forssmann's extensive work in the development of peptides for medical applications underscores his role as a leading inventor in the biomedical landscape. His contributions have paved the way for advancements that could significantly improve therapeutic strategies for various diseases, showcasing the impact of innovation in science and medicine.

Profile summary based on public USPTO records.